Seven Coinbase tokenized US stocks, including Apple and Tesla, can now be used as collateral for USDC loans on Aave V4 deployed on Base. These tokenized stocks represent real shares held by Alpaca Securities, with Coinbase as trustee, and pricing is provided by Chainlink's 24/5 feeds. Currently, the stocks serve as collateral only, allowing holders to borrow USDC without selling their shares, unlocking liquidity while maintaining exposure. This marks a significant step in integrating real-world assets into DeFi, with plans to add more tokenized stocks and borrowable assets like GHO in the future.
Coinbase tokenized stocks as collateral on Aave V4 provide context for digital asset markets. For readers following crypto markets, here is Pluang's snapshot as of Sep 25, 2026 23:02 WIB: out of 50 major cryptocurrencies, 35 rose and 14 fell. Notable movers include XRP at Rp28.295 with a 4.36% gain and a typical hold time of 71 days, XLM at Rp3.906 up 4.35%, and THETA at Rp4.068 with a 3.96% increase. The most notable figure is XRP's 56% sell order activity on Pluang.
Ivanhoe Electric's Santa Cruz Copper Mining Project in Arizona has strong economic potential, according to a recent Preliminary Feasibility Study. The project requires $1.43 billion in initial capital and expects low operating costs of $1.47 per poun...
Westlake, a global chemical and building materials company, has a revised analyst price target indicating a 46.27% potential upside from its current stock price. Institutional investors like Bank of America and others are increasing their holdings, r...
PayPal's stock rose following its announcement of a new strategic partnership with Meta Platforms, integrating AI-powered shopping across its merchant network. Deutsche Bank increased its price target for PayPal to $55 from $50, signaling potential u...
Golden Spike Resources Corp. announced it will change its name to Gordon Mining Group Inc. and consolidate its shares on a 5-for-1 basis, reducing the total shares from about 60.6 million to approximately 12.1 million. The share consolidation and nam...
Immunovant's stock fell about 6% to a three-month low after its IMVT-1402 cutaneous lupus study missed the primary endpoint, leading the company to discontinue the lupus program. This setback caused a sharp decline in share price, prompting a securit...
